Local adverse events: skin thinning; end of treatment (16‐20 weeks + 2‐4 weeks acute phase) · children and adults with mild to severe eczema
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (1 to 3 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults with mild to severe eczema
1 finding from 1 review
Systemic adverse events: abnormal cortisol; end of treatment (1‐6 weeks) · children and adults, most with moderate to severe eczema
1 finding from 1 review
Systemic adverse events: abnormal cortisol · adults with eczema
1 finding from 1 review
Local adverse events: skin thinning; end of treatment (1 to 3 weeks) · adults with eczema
It is very uncertain whether very potent changes local adverse events: skin thinning; end of treatment (day 11‐day 22) compared with potent topical corticosteroid (very low certainty).
1 finding from 1 review
Adverse events potentially related to Wolbachia‐carrying Aedes deployments · children and adults at risk of dengue infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment‐related AEs: total treatment‐emergent adverse events potentially related to treatment · adults with LOPD
Cipaglucosidase plus miglustat showed no clear difference in treatment‐related AEs: total treatment‐emergent adverse events… compared with alglucosidase alfa plus placebo (low certainty).
1 finding from 1 review
Treatment‐related AEs: total treatment‐emergent adverse events potentially related to treatment · adults with LOPD
Avalglucosidase alfa showed no clear difference in treatment‐related AEs: total treatment‐emergent adverse events… compared with alglucosidase alfa (low certainty).
1 finding from 1 review
Participants with adverse events ‐ potential immune‐mediated disease Clinical or laboratory criteria · healthy older adults aged ≥ 60 years
Recombinant zoster vaccine showed no clear difference in participants with adverse events ‐ potential immune‐mediated… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype
1 finding from 1 review
Adverse events · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events · adults with cystic fibrosis and with the F508del/MF genotype
1 finding from 1 review
Adverse events · adults with cystic fibrosis and with the F508del/MF genotype
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis and with at least one G551D CFTR mutation
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis and with at least one R117H CFTR mutation
1 finding from 1 review